Opko Health Inc (OPK)

[game7alcs]

OPKO Announces Third Quarter Operating and Financial Results
Rayaldee™ Meets Primary Endpoints in Both Pivotal Phase 3 Trials; NDA Submission Planned for Q4 2014
Rayaldee Results to be Presented at American Society of Nephrologists Meeting
Clinical Trial Start for Rayaldee as Adjunctive Cancer Therapy to Begin in Q4 2014
European Marketing Commenced for 4Kscore™ Blood Test to Identify Risk of Aggressive Prostate Cancer; Latin America Rollout Planned for Fourth Quarter 2014
Rolapitant™ NDA Submitted by OPKO Licensee Tesaro and Accepted for Review by FDA
Cash and Cash Equivalents of $118.3 Million Providing Adequate Liquidity To Fund Development Programs
hGH-CTP Development Program Continues to Progress Rapidly
Long Acting Factor VII for Hemophilia and Long Acting Oxyntomodulin for Obesity and Diabetes Clinical Trials to Begin During 2015